From Beach to Bedside: History of the Development of Sirolimus
Authors:
- Kimberly L. NapoliKNKimberly L. Napoli
- Paul J. TaylorPTPaul J. Taylor
- 1 October 2001
- journal article
- review article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 23 (5) , 559-586
Abstract
No abstract availableThis publication has 174 references indexed in Scilit:
- An immunoassay for the measurement of sirolimusClinical Therapeutics, 2000
- Introduction and overviewClinical Therapeutics, 2000
- Tissue Distribution and Abundance of Human FKBP51, an FK506-Binding Protein That Can Mediate Calcineurin InhibitionBiochemical and Biophysical Research Communications, 1997
- Pharmacokinetics of Prednisolone During Administration of Sirolimus in Patients with Renal TransplantsThe Journal of Clinical Pharmacology, 1996
- Inhibition by Rapamycin of P‐Glycoprotein 170‐Mediated Export from Normal LymphocytesScandinavian Journal of Immunology, 1996
- On the localization of FKBP25 in T‐lymphocytesFEBS Letters, 1993
- Effects of rapamycin on human HLA-unrestricted cell killingClinical Immunology and Immunopathology, 1992
- The effect of rapamycin on renal function in the rat: a comparative study with cyclosporineToxicology Letters, 1991
- Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin.Proceedings of the National Academy of Sciences, 1990
- A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilinNature, 1989